The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news release. Regeneron’s purchase does not include 23andMe’s Lemonaid Health business.

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and health information, genealogy, and other sensitive personal information—would be safe and in good hands.

Genetics company 23andMe is expected to be purchased by Regeneron Pharmaceuticals, according to announcements shared by both companies Both companies vowed that Regeneron is committed to comply with 23andMe's privacy policies,

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.